U.S. flag

An official website of the United States government

Format
Items per page
Sort by

Send to:

Choose Destination

Links from GEO DataSets

Items: 20

1.

KIF15 confers resistance to enzalutamide in castration resistant prostate cancer [array]

(Submitter supplied) The aim of this research was to confirm the regulatory effect of KIF15 on gene expression in castration resistant prostate cancer.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL13497
2 Samples
Download data: TXT
Series
Accession:
GSE146984
ID:
200146984
2.

KIF15 promotes AR and AR-V7 protein stabilization in contribution to enzalutamide resistance of prostate cancers

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Expression profiling by array; Expression profiling by high throughput sequencing
Platforms:
GPL16791 GPL13497
8 Samples
Download data: TXT
Series
Accession:
GSE150896
ID:
200150896
3.

KIF15 confers resistance to enzalutamide in castration resistant prostate cancer [RNA-Seq]

(Submitter supplied) The aim of this research was to confirm the regulatory effect of KIF15 on gene expression in castration resistant prostate cancer.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL16791
6 Samples
Download data: TXT
Series
Accession:
GSE150895
ID:
200150895
4.

Transcriptome analysis of Enzalutamide-resistant C4-2B (C4-2B MDVR) cells treated with Indocin.

(Submitter supplied) The overall goal of this study was to identify genes that were differentially-expressed in C4-2B MDVR cells treated with Indocin. C4-2B MDVR were either treated with Indocin (20 uM) or DMSO vehicle control for 3 days, followed by isolation of total cellular RNA. Transcriptome analysis was performed with RNA-Sequencing (RNA-Seq) in order to identify differentially-expressed genes (DEGs) induced by Indocin treatment.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL20301
2 Samples
Download data: TXT
5.

RNA-Seq analysis of prostate tumors with or without androgen receptor splice variant

(Submitter supplied) Background. Androgen receptor splice variant-7 (AR-V7) is a truncated form of the androgen receptor protein which lacks the ligand-binding domain, the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. We hypothesized that detection of AR-V7 in circulating tumor cells (CTCs) from men with advanced prostate cancer would be associated with resistance to enzalutamide and abiraterone. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL11154
4 Samples
Download data: TXT
6.

Profiles of prostate cancer cell lines

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Other; Expression profiling by high throughput sequencing
Platform:
GPL11154
32 Samples
Download data: TXT
Series
Accession:
GSE87153
ID:
200087153
7.

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor

(Submitter supplied) Prostate cancer is the most commonly diagnosed and second-most lethal cancer among men in the United States. The vast majority of prostate cancer deaths are due to castration-resistant prostate cancer (CRPC) – the lethal form of the disease that has progressed despite therapies that interfere with activation of androgen receptor (AR) signaling. One emergent resistance mechanism to medical castration is synthesis of intratumoral androgens that activate the AR. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL11154
30 Samples
Download data: TXT
8.

Role of androgen receptor splice variant 7 (AR-v7) in prostate cancer resistance to 2nd generation androgen receptor signaling inhibitors

(Submitter supplied) Since its discovery, there has been one central issue of significant clinical relevance related to expression of the truncated androgen receptor splice variant-7 (AR-v7), which lacks the C-terminal ligand binding domain and thus acquires ligand-independent transcriptional activity in castration-resistant prostate cancer (CRPC). That question is whether AR-v7 is simply a marker of enhanced AR transcriptional activity characteristic of resistance to 2nd generation androgen receptor signaling inhibitors (ARSi) like Abiraterone and Enzalutamide, or whether it drives lethal resistance to ARSi. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL16791
13 Samples
Download data: TXT
9.

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens; Mus musculus
Type:
Genome variation profiling by high throughput sequencing; Expression profiling by high throughput sequencing
Platforms:
GPL21290 GPL18573 GPL21493
223 Samples
Download data: TSV
Series
Accession:
GSE131986
ID:
200131986
10.

Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Expression profiling by array; Expression profiling by high throughput sequencing
Platforms:
GPL20301 GPL570
9 Samples
Download data: CEL, TXT
Series
Accession:
GSE120006
ID:
200120006
11.

Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer (Affymetrix)

(Submitter supplied) Constitutively active androgen receptor (AR) signaling confers resistance to AR-targeted therapies. Here we show that the ubiquitin-mediated proteolysis pathway plays a critical role in the degradation of AR and its variants, particularly variant 7 (AR-V7). AR/AR-V7 proteinhomeostasis (proteostasis) requires interaction of the E3 ubiquitin ligase STUB1 and HSP70complex. STUB1 disassociates AR/AR-V7 from HSP70, leading to AR/AR-V7 ubiquitination and degradation. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
3 Samples
Download data: CEL
Series
Accession:
GSE120005
ID:
200120005
12.

Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer (RNA-Seq)

(Submitter supplied) Constitutively active androgen receptor (AR) signaling confers resistance to AR-targeted therapies. Here we show that the ubiquitin-mediated proteolysis pathway plays a critical role in the degradation of AR and its variants, particularly variant 7 (AR-V7). AR/AR-V7 proteinhomeostasis (proteostasis) requires interaction of the E3 ubiquitin ligase STUB1 and HSP70complex. STUB1 disassociates AR/AR-V7 from HSP70, leading to AR/AR-V7 ubiquitination and degradation. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL20301
6 Samples
Download data: TXT
13.

Targeting DNMTs to overcome enzalutamide resistance in prostate cancer

(Submitter supplied) Prostate cancer is the second leading cause of cancer death among men in the United States. The androgen receptor (AR) antagonist enzalutamide is a FDA-approved drug for treatment of patients with late-stage prostate cancer and is currently under clinical study for early-stage prostate cancer treatment. After a short positive response period to enzalutamide, tumors will develop drug resistance. In this study, we uncovered that DNA methylation was deregulated in enzalutamide-resistant cells. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL20795
15 Samples
Download data: TXT
14.

RNA-seq control (sgNT) and TLE3KO (sgTLE3) cells treated with 10 uM enzalutamide or vehicle

(Submitter supplied) To investigate the transcriptional consequences of TLE3 loss in the presence/absence of AR inhibitor enzalutamide in prostate cancer cells, the transcriptomes of WT and TLE3KO cells treated with vehicle or enzalutamide (10 uM) were compared. .
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL16791
12 Samples
Download data: XLSX
15.

Endogenous Androgen Receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis

(Submitter supplied) Androgen Receptor (AR) is a key player in prostate cancer development and progression. Here, we applied immunoprecipitation mass spectrometry of endogenous AR in LNCaP cells to identify individual components of the AR transcription complex. In total, 66 known and novel AR interactors were identified in the presence of R1881, which were critically and selectively required in AR-driven prostate cancer cell proliferation. more...
Organism:
Homo sapiens
Type:
Genome binding/occupancy profiling by high throughput sequencing
Platform:
GPL16791
34 Samples
Download data: TXT
Series
Accession:
GSE94682
ID:
200094682
16.

Differential gene expression induced by Enzalutamide in a prostate cancer xenograft

(Submitter supplied) RNA-sequencing data of the prostate cancer xenograft PC346C-DCC-K model. Tumor bearing mice were treated daily with Enzalutamide (N=10, 60mg/kg) or placebo (N=5, vehicle) for a period of 7 days. Tumor were subsequently isolated and snap-frozen. Tumor tissue was lysed and homogenized in QIAzol (ref #79306, Qiagen, Hilden, Germany) using an Ultra-Turrax T25 (Janke & Kunkel, Staufen, Germany). Total RNA was isolated using the miRNA-easy mini kit (ref # 217004, Qiagen), and RNA quality was measured using the Bioanalyzer RNA 6000 Nano assay (ref #5067, Agilent, Santa Clara, California, USA). more...
Organism:
Homo sapiens; Mus musculus
Type:
Expression profiling by high throughput sequencing
Platform:
GPL25431
15 Samples
Download data: TXT
Series
Accession:
GSE185587
ID:
200185587
17.

J_093015-circRNA-33 AS-CR-005 Human CircRNA V2 microarray 01272016

(Submitter supplied) Background: Most forms of castration-resistant prostate cancer (CRPC) are dependent on the androgen receptor (AR) for survival. While, enzalutamide provides a substantial survival benefit, it is not curative and many patients develop resistance to therapy. Although not yet fully understood, resistance can develop through a number of mechanisms, such as AR copy number gain, the generation of splice variants such as AR-V7 and mutations within the ligand binding domain (LBD) of the AR. more...
Organism:
Homo sapiens
Type:
Non-coding RNA profiling by array
Platform:
GPL21825
9 Samples
Download data: TXT, XLSX
Series
Accession:
GSE118959
ID:
200118959
18.

Expression data from C42B prostate cancer cell line treated with enzalutamide and/or sphingosine kinase inhibitor PF-543 or ABC294640

(Submitter supplied) Epidemiological and molecular evidence indicate that sphingolipids may play a role in the resistance of prostate cancer to androgen receptor signalling inhibitors such as enzalutamide, through the metabolism of ceramide into sphingosine-1-phosphate (S1P) which activates specific G-protein coupled receptors present on cancer cells and immune cells. Sphingosine kinase inhibitors which prevent the production of S1P have anti-cancer effects in vitro and in animal models. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL23159
15 Samples
Download data: CEL
Series
Accession:
GSE173886
ID:
200173886
19.

Expression data from LNCaP cells treated with DHT and enzalutamide

(Submitter supplied) Enzalutamide (formerly MDV3100 and available commercially as Xtandi), a novel androgen receptor (AR) signaling inhibitor, blocks the growth of castration-resistant prostate cancer (CRPC) in cellular model systems and was shown in a clinical study to increase survival in patients with metastatic CRPC. Enzalutamide inhibits multiple steps of AR signaling: (1) binding of androgens to AR, (2) AR nuclear translocation, and (3) association of AR with DNA. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
18 Samples
Download data: CEL, TXT
Series
Accession:
GSE44905
ID:
200044905
20.

Expression data from prostate cancer LNCaP-AdtHs cells in response to androgen, ADT, normoxia, or hypoxia

(Submitter supplied) Androgen and hypoxia are two cancer hallmark pathways; both exert biological effects primarily via the regulation of gene expression We used gene expression array to determine the global gene expression changes due to androgen, castration (androgen-free) in normoxia and hypoxia conditions. Microarray assays were performed in the OHSU Gene Profiling Shared Resource
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL15207
12 Samples
Download data: CEL
Series
Accession:
GSE120343
ID:
200120343
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

db=gds|term=|query=2|qty=3|blobid=MCID_673214c0f73b361c5162e68b|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center